Portal de Periódicos da CAPES

The human splicing factors ASF/SF2 and SC35 possess distinct, functionally significant RNA binding specificities.

1995; Springer Nature; Volume: 14; Issue: 14 Linguagem: Inglês

10.1002/j.1460-2075.1995.tb07360.x

1460-2075

Roland Tacke, James L. Manley,

RNA modifications and cancer

Research Article17 July 1995free access The human splicing factors ASF/SF2 and SC35 possess distinct, functionally significant RNA binding specificities. R. Tacke R. Tacke Department of Biological Sciences, Columbia University, New York, NY 10027, USA. Search for more papers by this author J.L. Manley J.L. Manley Department of Biological Sciences, Columbia University, New York, NY 10027, USA. Search for more papers by this author R. Tacke R. Tacke Department of Biological Sciences, Columbia University, New York, NY 10027, USA. Search for more papers by this author J.L. Manley J.L. Manley Department of Biological Sciences, Columbia University, New York, NY 10027, USA. Search for more papers by this author Author Information R. Tacke1 and J.L. Manley1 1Department of Biological Sciences, Columbia University, New York, NY 10027, USA. The EMBO Journal (1995)14:3540-3551https://doi.org/10.1002/j.1460-2075.1995.tb07360.x PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info ASF/SF2 and SC35 belong to a highly conserved family of nuclear proteins that are both essential for splicing of pre-mRNA in vitro and are able to influence selection of alternative splice sites. An important question is whether these proteins display distinct RNA binding specificities and, if so, whether this influences their functional interactions with pre-mRNA. To address these issues, we first performed selection/amplification from pools of random RNA sequences (SELEX) with portions of the two proteins comprising the RNA binding domains (RBDs). Although both molecules selected mainly purine-rich sequences, comparison of individual sequences indicated that the motifs recognized are different. Binding assays performed with the full-length proteins confirmed that ASF/SF2 and SC35 indeed have distinct specificities, and at the same time provided evidence that the highly charged arginine-serine region of each protein is not a major determinant of specificity. In the case of ASF/SF2, evidence is presented that binding specificity involves cooperation between the protein's two RBDs. Finally, we demonstrate that an element containing three copies of a high-affinity ASF/SF2 binding site constitutes a powerful splicing enhancer. In contrast, a similar element consisting of three SC35 sites was inactive. The ASF/SF2 enhancer can be activated specifically in splicing-deficient S100 extracts by recombinant ASF/SF2 in conjunction with one or more additional protein factors. These and other results suggest a central role for ASF/SF2 in the function of purine-rich splicing enhancers. Previous ArticleNext Article Volume 14Issue 141 July 1995In this issue RelatedDetailsLoading ...